BiotechTube
RAN biotechnologies

RAN biotechnologies

Cambridge, United States· Est.
ranbiotechnologies.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $14.5M

Overview

RAN Biotechnologies is a private, revenue-generating tools and reagents company founded in 2012 (not 2019 as per some data) and based in Beverly, Massachusetts. It develops and commercializes specialized fluorinated surfactants, oils, microfluidic chips, and the Rapid Microbe Detection (RMD) system, serving researchers in life sciences, environmental monitoring, and energy sectors. The company's business model is built on selling platform technologies and consumables to enable advanced research, rather than developing its own therapeutic drugs. Its mission centers on providing innovative tools to address urgent needs in human health and the environment.

RNA TherapeuticsOncology

Technology Platform

Specialized fluorochemistry and microfluidics for creating tools and reagents, including fluorosurfactants, oils, microfluidic chips, and nanomaterials for rapid microbial detection.

Funding History

2
Total raised:$14.5M
Series A$12M
Seed$2.5M

Opportunities

The growing markets for single-cell analysis and next-generation sequencing create sustained demand for high-performance microfluidic components.
The Rapid Microbe Detection system has potential for expansion from environmental research into adjacent fields like industrial water safety, food testing, and public health monitoring, where rapid, on-site results are valuable.

Risk Factors

Revenue is dependent on the continued adoption and funding for droplet microfluidic technologies in research.
The company faces competition from larger reagent suppliers and must protect its proprietary formulations.
Commercializing the Rapid Microbe Detection system requires displacing established, slower methods and building new sales channels.

Competitive Landscape

RAN Biotech competes in the niche market for fluorinated microfluidic reagents against specialized chemical companies and divisions of larger life science tools providers (e.g., Merck, Avanti). In rapid microbial detection, it faces competition from established microbiology methods and emerging molecular diagnostic platforms. Its differentiation lies in its deep fluorochemistry expertise and focus on creating integrated, field-ready tools for scientists.

More companies in United States →